AU2003258662A1 - Use of 4-amino-quinazolines as anti cancer agents - Google Patents

Use of 4-amino-quinazolines as anti cancer agents

Info

Publication number
AU2003258662A1
AU2003258662A1 AU2003258662A AU2003258662A AU2003258662A1 AU 2003258662 A1 AU2003258662 A1 AU 2003258662A1 AU 2003258662 A AU2003258662 A AU 2003258662A AU 2003258662 A AU2003258662 A AU 2003258662A AU 2003258662 A1 AU2003258662 A1 AU 2003258662A1
Authority
AU
Australia
Prior art keywords
quinazolines
amino
cancer agents
anti cancer
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003258662A
Inventor
Gerhard Barnickel
Hans-Michael Eggenweiler
Volker Eiermann
Rolf Gericke
Wilfried Rautenberg
Burkhard Scharm
Christian Sirrenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of AU2003258662A1 publication Critical patent/AU2003258662A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003258662A 2002-10-02 2003-08-25 Use of 4-amino-quinazolines as anti cancer agents Abandoned AU2003258662A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02022152.9 2002-10-02
EP02022152 2002-10-02
PCT/EP2003/009391 WO2004030671A2 (en) 2002-10-02 2003-08-25 Use of 4-amino-quinazolines as anti cancer agents

Publications (1)

Publication Number Publication Date
AU2003258662A1 true AU2003258662A1 (en) 2004-04-23

Family

ID=32049972

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003258662A Abandoned AU2003258662A1 (en) 2002-10-02 2003-08-25 Use of 4-amino-quinazolines as anti cancer agents

Country Status (2)

Country Link
AU (1) AU2003258662A1 (en)
WO (1) WO2004030671A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1797096B1 (en) 2004-09-06 2011-07-27 Bayer Schering Pharma Aktiengesellschaft Pyrazolopyrimidines as inhibitors of protein kinase b (akt)
MX2010004718A (en) 2007-11-01 2010-07-28 Acucela Inc Amine derivative compounds for treating ophthalmic diseases and disorders.
EP2241565A1 (en) 2009-01-15 2010-10-20 Universität Leipzig Aurora kinase inhibitors compounds
EP3575288B1 (en) 2009-09-03 2021-10-27 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
US8993552B2 (en) 2009-09-04 2015-03-31 The Regents Of The University Of Michigan Compositions and methods for treatment of leukemia
JP2016529250A (en) * 2013-08-09 2016-09-23 ヴィケム ケミー クタト ケイエフティー． Styrylquinazoline derivatives as pharmaceutically active agents
US10246464B2 (en) 2014-09-09 2019-04-02 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
WO2016197027A1 (en) 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
TWI703150B (en) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 Methods and compositions for inhibiting the interaction of menin and mll proteins
HUE061989T2 (en) 2016-03-16 2023-09-28 Kura Oncology Inc Substituted thieno[2,3-d]pyrimidine derivatives as inhibitors of menin-mll and methods of use
WO2017161002A1 (en) 2016-03-16 2017-09-21 Kura Oncology, Inc. Bridged bicyclic inhibitors of menin-mll and methods of use
JP2020514388A (en) 2017-03-24 2020-05-21 クラ オンコロジー，インク． Methods for treating hematological malignancies and Ewing sarcoma
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
TW201920170A (en) 2017-09-20 2019-06-01 美商庫拉腫瘤技術股份有限公司 Substituted inhibitors of MENIN-MLL and methods of use
KR102490434B1 (en) * 2020-09-25 2023-01-19 한양대학교 에리카산학협력단 Novel quinazoline derivatives having FLT3-inhibitory activity and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
US20020025968A1 (en) * 1998-04-15 2002-02-28 Rifat Pamukcu Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives
EE200100302A (en) * 1998-12-02 2002-08-15 Pfizer Products Inc. Methods and compositions for restoring conformational stability of p53 family protein
WO2000077246A2 (en) * 1999-06-14 2000-12-21 Novo Nordisk A/S A METHOD FOR IDENTIFYING A DRUG CANDIDATE HAVING AN INHIBITORY ACTION ON FVII-TF ACTIVITY, AND FVIIa/TF ACTIVITY INHIBITING COMPOUNDS
JP3649395B2 (en) * 2000-04-27 2005-05-18 山之内製薬株式会社 Fused heteroaryl derivatives

Also Published As

Publication number Publication date
WO2004030671A2 (en) 2004-04-15
WO2004030671A3 (en) 2004-06-10

Similar Documents

Publication Publication Date Title
AU2003255482A1 (en) Use of 4 amino-quinazolines as anti cancer agents
WO2003073826A8 (en) Novel compositions and methods for cancer
AU2003213144A1 (en) Alkylating agent combinations in the treatment of cancer
AU2003286263A1 (en) Complexes of receptors
AU2003304507A1 (en) Anti-coronavirus agent
AU2003212634A1 (en) Compounds useful in the treatment of cancer
AU2003258662A1 (en) Use of 4-amino-quinazolines as anti cancer agents
AU2003292263A1 (en) Use of substituted 2-phenylbenzimidazoles as medicaments
AU2003220968A1 (en) Anti-inflammatory agent
AU2003247005A1 (en) Therapy combination
AU2003227489A1 (en) Skin protecting compositions
AU2003299100A1 (en) Pyrimidine compounds as therapeutic agents
AU2003245794A1 (en) Glycosaminoglycan-dnase combination therapy
AU2003275505A1 (en) Electowinning of metals
AU2003223538A1 (en) Methods for the treatment of cancer
AU2003219160A1 (en) Methods and compositions for the treatment of cancer
AU2003215150A1 (en) Therapeutic compounds
AU2003224000A1 (en) Compounds useful as photodynamic therapeutic agents
AU2003289207A1 (en) Anti-inflammatory agent
AU2003282722A1 (en) Therapeutic compositions
AU2003290818A1 (en) Topoisomerase-targeting agents
AU2003231803A1 (en) Treatment of cancer with mefloquire
AU2003283339A1 (en) Cancer therapy determination
AU2003232189A1 (en) Antifouling agent
AU2003296242A1 (en) Thia-epothilone derivatives for the treatment of cancer

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase